Glutathione: Does oral glutathione increase glutathione—and what does that change?

Why It Matters #

Glutathione is a tripeptide made from glutamate, cysteine and glycine. Inside cells, its reduced and oxidized forms participate in redox regulation and peroxide handling. The biological importance of this system is well established; whether additional oral glutathione improves a particular human outcome is a separate intervention question.

What Was Studied #

Trials include standard reduced glutathione at 250–1,000 mg/day, small liposomal studies and newer formulation-specific pharmacokinetic comparisons. Blood, erythrocytes, lymphocytes and buccal cells are different measurement compartments. Studies of precursors or combinations, including GlyNAC, cannot be treated as trials of glutathione alone.[1][2][3][4]

What Was Found #

A six-month randomized trial in 54 healthy nonsmokers reported increased glutathione stores with 250 or 1,000 mg/day. In contrast, a four-week placebo-controlled trial using 1,000 mg/day found no significant difference in glutathione status or oxidative-stress markers. Duration, participants and assays could contribute to the discrepancy; these studies do not isolate its cause.[1][2]

A 14-person crossover study reported higher short-term exposure with a micellar preparation than a standard preparation. It compared unequal administered doses, and its subsequent 30-day phase had no parallel placebo group. This is evidence about the tested formulation and pharmacokinetics, not comparative disease prevention.[4]

What the Evidence Means #

The answer to “does oral glutathione work?” depends on the endpoint. Measurable increases are possible in some studies. The reviewed biomarker trials do not show that the increase prevents disease, preserves long-term function or improves survival. A liposomal label alone does not establish superiority: the early pilot lacked a placebo group.[3]

What We Can Learn #

For a formulation claim, look for an equal-dose comparison, a prespecified concentration measure and a clinical outcome. Percentage increases from baseline should not be presented as placebo-adjusted effects. The small studies below are more informative about exposure and short-term tolerability than uncommon adverse events or long-term benefit.

What Remains Unknown #

The key unresolved question is which people benefit clinically from a sustained rise in glutathione, and whether different delivery systems change that benefit rather than just the blood curve. Independent, adequately powered head-to-head trials and longer safety follow-up remain important.

Primary Sources and updates

1. Richie JP, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European journal of nutrition DOI: 10.1007/s00394-014-0706-zOriginal abstract and bibliographic record reviewed; unavailable full-text details are not inferred.
2. Allen J, Bradley RD. (2011). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of alternative and complementary medicine (New York, N.Y.) DOI: 10.1089/acm.2010.0716Original abstract and bibliographic record reviewed; unavailable full-text details are not inferred.
3. Sinha R, Sinha I, Calcagnotto A, Trushin N, Haley JS, Schell TD, Richie JP. (2018). Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European journal of clinical nutrition DOI: 10.1038/ejcn.2017.132Bibliographic record; not a detailed study appraisal.
4. Solnier J, Du M, Zhang Y, Roh YS, Kuo YC, Ibi A, Wood S, Hardy M, Gahler RJ, Chang C. (2026). A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial. Antioxidants (Basel, Switzerland) DOI: 10.3390/antiox15030354Original full text and bibliographic record reviewed.
5. Søndergård SD, Cintin I, Kuhlman AB, Morville TH, Bergmann ML, Kjær LK, Poulsen HE, Giustarini D, Rossi R, Dela F, Helge JW, Larsen S. (2021). The effects of 3 weeks of oral glutathione supplementation on whole body insulin sensitivity in obese males with and without type 2 diabetes: a randomized trial. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme DOI: 10.1139/apnm-2020-1099Bibliographic record; not a detailed study appraisal.
6. Duperray J, Sergheraert R, Chalothorn K, Tachalerdmanee P, Perin F. (2022). The effects of the oral supplementation of L-Cystine associated with reduced L-Glutathione-GSH on human skin pigmentation: a randomized, double-blinded, benchmark- and placebo-controlled clinical trial. Journal of cosmetic dermatology DOI: 10.1111/jocd.14137Bibliographic record; not a detailed study appraisal.
7. Sitohang IBS, Anwar AI, Jusuf NK, Arimuko A, Norawati L, Veronica S. (2021). Evaluating Oral Glutathione Plus Ascorbic Acid, Alpha-lipoic Acid, and Zinc Aspartate as a Skin-lightening Agent: An Indonesian Multicenter, Randomized, Controlled Trial. The Journal of clinical and aesthetic dermatologyBibliographic record; not a detailed study appraisal.
8. Sarkar R, Yadav V, Yadav T, P J, Mandal I. (2025). Glutathione as a skin-lightening agent and in melasma: a systematic review. International journal of dermatology DOI: 10.1111/ijd.17535Bibliographic record; not a detailed study appraisal.
9. Figueroa A, Maharaj A, Kang Y, Dillon KN, Martinez MA, Morita M, Nogimura D, Fischer SM. (2023). Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women. Nutrients DOI: 10.3390/nu15071557Bibliographic record; not a detailed study appraisal.
10. Mawu FO, Anwar AI, Djawad K, Bukhari A, Kapantow MG, Christopher PM. (2025). Effectiveness of oral glutathione in reducing nitric oxide and IL-1α concentrations for clinical improvement in mild to moderate acne vulgaris: a randomized controlled trial. Acta dermatovenerologica Alpina, Pannonica, et AdriaticaBibliographic record; not a detailed study appraisal.

First published: 2026-09-27 / Version 1.0. Sources reviewed 2026-09-27. Funding and conflicts are recorded separately; an unverified disclosure is not a declaration of no funding or no conflict.